Analysis of the efficiency and safety of using the slow-release calcium channel blocker nifedipine as a tocolytic drug in pregnant women with preterm labor


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Preterm labor (PL) remains one of the major problems of modern obstetrics all over the world, which is due to the unresolved issues concerning etiology, pathogenesis, clinical presentation, diagnosis, and rational pharmacotherapy. PL complications are the main cause of neonatal death worldwide; with the surviving infants facing the risk of serious neonatal complications and long-term disability. In the course of prioritization work, the WHO has placed PL in the top 10 research priorities for the period up to 2025. The investigations aimed at preventing PL and reducing perinatal mortality are also a key component of the UN global strategy for sustainable development until 2030. The development and introduction of technologies for personalized medicine are ways to optimize tocolytic therapy in pregnant women with PL, which are regulated in the Russian Strategy for the Development of Medical Science until 2025.

Full Text

Restricted Access

About the authors

K. O Akopov

S.S. Yudin City Clinical Hospital, Moscow Healthcare Department

E. V Zhukova

I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia

Candidate of Medical Sciences

E. A Sokova

Research Center for Examination of Medical Products, Ministry of Health of Russia

Candidate of Medical Sciences

R. A Chilova

I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia

Email: rchilova@gmail.com

References

  1. Инструкция по применению лекарственного препарата для медицинского применения Нифедипин. Государственный реестр лекарственных средств [Instruktsiya po primeneniyu lekarstvennogo preparata dlya meditsinskogo primeneniya Nifedipin. Gosudarstvennyi reestr lekarstvennykh sredstv (in Russ.)]. URL: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=b0cb1df0-3494-4405-88fd-78b9995872fd&t=
  2. Клинические рекомендации «Преждевременные роды» (утв. Минздравом России) [Klinicheskie rekomendatsii «Prezhdevremennye rody» (utv. Minzdravom Rossii) (in Russ.)]. URL: http://cr.rosminzdrav.ru/
  3. Лепахин В.К. и др. Неблагоприятные побочные реакции, вызываемые токолитическими препаратами. Безопасность лекарств и фармаконадзор. 2009; 2: 29-38 [Lepakhin V.K. i dr. Neblagopriyatnye pobochnye reaktsii, vyzyvaemye tokoliticheskimi preparatami. Bezopasnost lekarstv i farmakonadzor. 2009; 2: 29-38 (in Russ.)].
  4. Назарова А.О., Малышкина А.И., Назаров С.Б. Факторы риска спонтанных преждевременных родов: результаты клинико-эпидемиологического исследования. Акушерство и гинекология. 2019; 9: 82-6 [Nazarova A.O., Malyshkina A.I., Nazarov S.B. Risk factors for spontaneous preterm birth: results of a clinical-epidemiological study. Akusherstvo i Ginekologiya = Obstetrics and Gynecology. 2019; 9: 82-6 (in Russ.)]. https://dx.doi. org/10.18565/aig.2019.9.82-86
  5. Персонализированная медицина: клинико-фармакологические аспекты. Под ред. В.Г. Кукеса М.: Издательство АГО Международная ассоциация клинических фармакологов и фармацевтов, 2014; 260 с. [Personalizirovannaya meditsina: kliniko-farmakologicheskie aspekty. Pod red. V.G. Kukesa М.: Izdatel’stvo AGO Mezhdunarodnaya assotsiatsiya klinicheskikh farmakologov i farmatsevtov, 2014; 260 s. (in Russ.)].
  6. Серов В.Н., Сухорукова О.И. Профилактика преждевременных родов. РМЖ. 2014; 1: 3-10 [Serov V.N., Sukhorukova O.I. Profilaktika prezhdevremennykh rodov. RMZh. 2014; 1: 3-10 (in Russ.)].
  7. Armstrong J., Goldfarb A., Instrum R. et al. Improvement evident but still necessary in clinical practice guideline quality: a systematic review. J Clin Epidemiol. 2017; 81: 13-21. doi: 10.1016/j.jclinepi.2016.08.005
  8. Saleh S.S., Al-Ramahi M.Q., Al Kazaleh F.A. Atosiban and nifedipine in the suppression of pre- term labour: a comparative study. J Obstet Gynaecol. 2013; 33: 43-5. doi: 10.3109/01443615.2012.721822
  9. Ashraf B. Efficacy and safety of oral nifedipine with or without vaginal progesterone in the management of threatened preterm labor. J Reprod Biomed (Yazd). 2019; 17 (9): 629-36. doi: 10.18502/ijrm.v17i9.5098
  10. Berger I., Abele H., Bahlmann F. et al. Prevention and Therapy of Preterm Birth. Guideline of the DGGG, OEGGG and SGGG (S2k Level, AWMF Registry Number 015/025, February 2019) - Part 2 with Recommendations on the Tertiary Prevention of Preterm Birth and the Management of Preterm Premature Rupture of Membranes. Geburtshilfe Frauenheilkd. 2019; 79 (8): 813-33. doi: 10.1055/a-0903-2735
  11. Clinical practice guideline tocolytic treatment in pregnancy. Institute of Obstetricians and Gynaecologists, Royal College of Physicians of Ireland And Directorate of Strategy and Clinical Care Health Service Executive. Version 1.0 Date of publication: April 2013 Guideline No.22 Revision date: April 2015.
  12. Sachar М., Kelly E.J., Unadkat J.D. Mechanisms of CYP3A Induction During Pregnancy: Studies in HepaRG Cells. AAPS J. 2019; 21 (3): 45. DOI: 10.1208/ s12248-019-0316-z
  13. Seredina T.A., Goreva O.B., Talaban V.O. et al. Association of cytochrome P450 genetic polymorphisms with neoadjuvant chemotherapy efficacy in breast cancer patients. BMC Med Genet. 2012; 13 (1): 45. doi: 10.1186/1471-2350-13-45
  14. Talati A.N., Hackney D.N., Mesiano S. Pathophysiology of preterm labor with intact membranes. Semin Perinatol. 2017; 41 (7): 420-6. DOI: 10.1053/j. semperi.2017.07.013
  15. Vogel J.P., Oladapo O.T., Manu A. New WHO recommendations to improve the outcomes of preterm birth. Lancet Glob Health. 2015; 3: e589-e590. doi: 10.1016/S2214-109X(15)00183-7
  16. Yamasato K., Burlingame J., Kaneshiro B. Hemodynamic effects of nifedipine tocolysis. J Obstet Gynaecol Res. 2015; 41: 17-22. DOI: 10.1111/ jog.12478

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2021 Russkiy Vrach Publishing House

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies